Adverse reactions in adults and adolescents in the pivotal study at 24 weeks1
41% (36/88) of patients who received Oxbryta required a dose modification
5% (4/88) permanently discontinued therapy due to an adverse reaction (Grade 1-4)
Most frequent adverse reactions requiring dosage interruption occurring in more than 1 patient who received Oxbryta 1,500 mg included diarrhea, headache, rash, and vomiting. Patients needing a temporary modification based on physician discretion/adverse reaction severity could be lowered to 1,200 mg/day until the event subsided and patients could return to 1,500 mg/day2
Adverse reactions (≥10%) in patients receiving Oxbryta with a difference between arms of >3% compared to placebo
1,500 mg (n=88)
Serious adverse reactions that occurred in 3% (3/88) of patients receiving Oxbryta included headache, drug hypersensitivity, and pulmonary embolism occurring in one patient each
Clinically relevant adverse reactions occurring in <10% of patients included drug hypersensitivity
*Adverse reactions were Grade 1 or 2 except for Grade 3 diarrhea (n=1), nausea (n=1), rash (n=1), and rash generalized (n=3).
†Abdominal pain (grouped PTs) included the following PTs: abdominal pain and upper abdominal pain.
‡Rash (grouped PTs) includes the following PTs: rash, urticaria, generalized rash, maculo-papular rash, pruritic rash, papular rash, erythematous rash, and vesicular rash.
You are now leaving Global Blood Therapeutics’ site and moving to an external website independently operated and not managed by Global Blood Therapeutics. Global Blood Therapeutics assumes no responsibility for the site(s) you're visiting. If you do not wish to leave this site, click Cancel, or click OK to continue.
A message from Dr. Ted W. Love
President and CEO, Global Blood Therapeutics, Inc.
Thank you for visiting the NMA 2020 Virtual Conference!
We are proud to participate in this important meeting and appreciate your interest in learning more about GBT and Oxbryta® (voxelotor) tablets. We at GBT share your passion and commitment to improving the lives of patients. Together, we can make a difference.
I encourage you to explore our website to learn more about Oxbryta.
NEJM does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in NEJM reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated. NEJM reprints are not intended as the sole source of clinical information on this topic. Readers are advised to search the NEJM website at www.nejm.org and other medical sources for relevant clinical information on this topic. Reprints of articles published in NEJM are distributed only as free-standing educational material. They are not intended to endorse or promote any organization or its products or services.
If you do not wish to leave this site, click Cancel, or click Ok to continue.